NASDAQ:AFMD

Affimed - AFMD Stock Forecast, Price & News

$2.00

-0.03 (-1.48%)

(As of 09/23/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.95
▼
$2.08
50-Day Range: $2.00
▼
$3.32
52-Week Range: $1.93
▼
$7.35

Volume: 1.19 million shs
Average Volume: 1.26 million shs
Market Capitalization: $246.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Affimed MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 400.0% Upside
$10.00 Price Target
Short Interest: Healthy
3.28% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.95
Upright™ Environmental Score
News Sentiment: 0.64
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.67) to ($0.81) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

303rd out of 1,080 stocks

Pharmaceutical Preparations Industry

125th out of 535 stocks

3.5

Analyst's Opinion

Consensus Rating
Affimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Affimed has a forecasted upside of 400.0% from its current price of $2.00.
Amount of Analyst Coverage
Affimed has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.28% of the outstanding shares of Affimed have been sold short.
Short Interest Ratio / Days to Cover
Affimed has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Affimed has recently decreased by 6.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Affimed does not currently pay a dividend.
Dividend Growth
Affimed does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Affimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.
Environmental Sustainability
The Environmental Impact score for Affimed is -1.95.

2.6

News and Social Media Coverage

News Sentiment
Affimed has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Affimed this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for AFMD on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Affimed insiders have not sold or bought any company stock.
Percentage Held by Institutions
71.08% of the stock of Affimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Affimed are expected to decrease in the coming year, from ($0.67) to ($0.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Affimed is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Affimed is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Affimed has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Affimed (NASDAQ:AFMD) Stock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Stock News Headlines

September 19, 2022 | americanbankingnews.com

Affimed (NASDAQ:AFMD) Receives $10.00 Consensus PT from Analysts

September 12, 2022 | finance.yahoo.com

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet? - Yahoo Finance

September 12, 2022 | finance.yahoo.com

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

September 5, 2022 | globenewswire.com

Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022 - GlobeNewswire

September 4, 2022 | finance.yahoo.com

Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022

August 24, 2022 | nasdaq.com

Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks - Nasdaq

August 24, 2022 | fool.com

Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks - The Motley Fool

August 20, 2022 | finance.yahoo.com

Calculating The Intrinsic Value Of Affimed N.V. (NASDAQ:AFMD)

August 12, 2022 | seekingalpha.com

Affimed GAAP EPS of -€0.13, revenue of €7.3M (NASDAQ:AFMD) - Seeking Alpha

August 11, 2022 | seekingalpha.com

AFMD stock on watch on plans to pull U.S. trial for leukemia drug (NASDAQ:AFMD) - Seeking Alpha

August 11, 2022 | benzinga.com

Recap: Affimed Q2 Earnings - Benzinga

August 11, 2022 | investing.com

Affimed Reports Q2 EPS of EUR (0.13) By Investing.com - Investing.com

August 11, 2022 | globenewswire.com

Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress - GlobeNewswire

August 10, 2022 | seekingalpha.com

Affimed Q2 2022 Earnings Preview (NASDAQ:AFMD) - Seeking Alpha

August 10, 2022 | benzinga.com

Preview: Affimed's Earnings

August 4, 2022 | businesswire.com

Natural Killer (NK) Cell Therapeutics Market, 2032 - ResearchAndMarkets.com - Business Wire

August 4, 2022 | finance.yahoo.com

Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

July 27, 2022 | nasdaq.com

7 Undervalued Biotech Stocks to Buy Before They Boom - Nasdaq

July 26, 2022 | finance.yahoo.com

Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board - Yahoo Finance

July 26, 2022 | streetinsider.com

Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board - StreetInsider.com

July 25, 2022 | investorplace.com

7 Undervalued Biotech Stocks to Buy Before They Boom - InvestorPlace

July 15, 2022 | nasdaq.com

Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth? - Nasdaq

July 15, 2022 | finance.yahoo.com

Affimed (NASDAQ:AFMD) shareholders have endured a 57% loss from investing in the stock a year ago - Yahoo Finance

July 13, 2022 | finance.yahoo.com

Affimed (NASDAQ:AFMD) shareholders have endured a 57% loss from investing in the stock a year ago

July 12, 2022 | nasdaq.com

UnitedHealth (UNH) to Post Q2 Earnings: What to Expect? - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Company Calendar

Last Earnings: 8/11/2022
Today: 9/24/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AFMD
CUSIP: N/A
CIK: 1608390
Web: www.affimed.com
Phone: 496221674360
Fax: 49-6221-653-0777
Employees: 197
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +400.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,060,000.00
Net Margins: -232.11%
Pretax Margin: -223.00%
Return on Equity: -54.94%
Return on Assets: -35.29%

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 4.90
Quick Ratio: 4.89

Sales & Book Value

Annual Sales: $47.76 million
Price / Sales: 5.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.30 per share
Price / Book: 1.54

Miscellaneous

Outstanding Shares: 123,420,000
Free Float: N/A
Market Cap: $246.84 million
Optionable: Optionable
Beta: 2.32

Key Executives

Dr. Adi Hoess (Age 61)
CEO, MD & Member of Management Board
Comp: $786.03k

Mr. Angus W. Smith (Age 40)
CFO & Member of Management Board
Comp: $566.18k

Dr. Wolfgang Fischer (Age 58)
MD, COO & Member of Management Board
Comp: $619.39k

Ms. Denise Mueller (Age 53)
Chief Bus. Officer & Member of Management Board
Comp: $540.08k

Dr. Andreas Harstrick M.D. (Age 61)
Chief Medical Officer & Member of Management Board
Comp: $513.98k

Dr. Arndt J. G. Schottelius M.D. (Age 56)
Ph.D., Chief Scientific Officer & Member of Management Board
Comp: $621.39k

Prof. Melvyn Little
Founder & Consultant

Mr. Michael Wolf (Age 55)
Head of Fin. & Admin.

Mr. Alexander Fudukidis
Head of Investor Relations

Dr. Uwe Reusch
Head of Cell Culture

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AFMD Stock - Frequently Asked Questions

Should I buy or sell Affimed stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings or view top-rated stocks.
What is Affimed's stock price forecast for 2022?: 7 Wall Street analysts have issued 1-year target prices for Affimed's shares. Their AFMD share price forecasts range from $7.00 to $12.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts.
How have AFMD shares performed in 2022?: Affimed's stock was trading at $5.52 at the beginning of the year. Since then, AFMD shares have decreased by 63.8% and is now trading at $2.00.
View the best growth stocks for 2022 here.
When is Affimed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our AFMD earnings forecast.
How were Affimed's earnings last quarter?: Affimed (NASDAQ:AFMD) released its quarterly earnings data on Thursday, August, 11th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The biopharmaceutical company earned $7.78 million during the quarter, compared to analysts' expectations of $8.12 million. Affimed had a negative trailing twelve-month return on equity of 54.94% and a negative net margin of 232.11%.
What other stocks do shareholders of Affimed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).

What is Affimed's stock symbol?: Affimed trades on the NASDAQ under the ticker symbol "AFMD."
Who are Affimed's major shareholders?: Affimed's stock is owned by many different retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (5.23%), Pictet Asset Management SA (3.88%), Woodline Partners LP (2.03%), State Street Corp (1.82%), Bain Capital Public Equity Management II LLC (1.03%) and Northern Trust Corp (0.80%).
How do I buy shares of Affimed?: Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Affimed's stock price today?: One share of AFMD stock can currently be purchased for approximately $2.00.
How much money does Affimed make?: Affimed (NASDAQ:AFMD) has a market capitalization of $246.84 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.
How many employees does Affimed have?: The company employs 197 workers across the globe.
How can I contact Affimed?: Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 9/24/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

Affimed - AFMD Stock Forecast, Price & News

Affimed MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability